Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment. (11th February 2020)

• Record Type: Journal Article
• Authors: Kile, Shawn; Au, William; Parise, Carol; Sohi, Jaideep; Yarbrough, Tracy; Czeszynski, Alan; Johnson, Ken; Redline, Dan; Donnel, Tammy; Hankins, Andrea; Rose, Kimberley
• Is Part Of: American journal of Alzheimer's disease & other dementias. Volume 35(2020)
• Publication Date: 2020-02-11
• Subjects: intravenous immunoglobulin -- mild cognitive impairment -- Alzheimer's -- disease -- amyloid -- Aβ -- PET; Alzheimer's disease -- Periodicals; Dementia -- Periodicals; Alzheimer's disease -- Patients -- Care -- United States -- Periodicals; 616.83
• DOI: 10.1177/1533317519899800
• Languages: English
• ISSNs: 1533-3175

Abstract

Objective: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS). Methods: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed. Results: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye. Conclusions: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.